Literature DB >> 17029128

No effect of pyridoxine on the incidence of myelosuppression during prolonged linezolid treatment.

D Plachouras1, E Giannitsioti, S Athanassia, F Kontopidou, A Papadopoulos, K Kanellakopoulou, H Giamarellou.   

Abstract

Complications of long-term linezolid administration include anemia and thrombocytopenia. A recent report has suggested that pyridoxine may prevent myelosuppression. Pyridoxine was administered to 24 patients with bone infections who were being treated with linezolid. Thrombocytopenia occurred in 11 patients (45.8%), and anemia occurred in 6 (25%). We concluded that treatment wtih pyridoxine is unlikely to benefit patients who have been receiving linezolid for >2 weeks.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17029128     DOI: 10.1086/508280

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  5 in total

Review 1.  Linezolid-induced thrombocytopenia in impaired renal function: is it time for a dose adjustment? A case report and review of literature.

Authors:  A P Cossu; M Musu; P Mura; L M De Giudici; G Finco
Journal:  Eur J Clin Pharmacol       Date:  2014-01       Impact factor: 2.953

2.  Linezolid use for drug-resistant tuberculosis in Georgia: a retrospective cohort study.

Authors:  L Mikiashvili; M Kipiani; M C Schechter; Z Avaliani; N Kiria; R R Kempker
Journal:  Int J Tuberc Lung Dis       Date:  2020-04-01       Impact factor: 2.373

3.  Safety and Tolerability of More than Six Days of Tedizolid Treatment.

Authors:  Mireia Mensa Vendrell; Maria Tasias Pitarch; Miguel Salavert Lletí; Eva Calabuig Muñoz; Laura Morata Ruiz; Genís Castells Lao; Ester López Suñé; Jose Mensa Pueyo; Maria Rosa Oltra Sempere; Maria-Luisa Pedro-Botet Montoya; Valentina Isernia; Esteban Alberto Reynaga Sosa; Leonor Moreno Nuñez; Juan Pasquau Liaño; Sergio Sequera Arquelladas; José Ramón Yuste Ara; Alex Soriano Viladomiu
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

4.  Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid.

Authors:  Alex Soriano; Mar Ortega; Sebastián García; Georgina Peñarroja; Albert Bové; Miguel Marcos; Juan C Martínez; José A Martínez; Josep Mensa
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

5.  Effects of vitamin b6 therapy for sepsis patients with linezolid-associated cytopenias: a retrospective study.

Authors:  Jie Deng; Long-Xiang Su; Zhi-Xin Liang; Li-Ling Liang; Peng Yan; Yan-Hong Jia; Xin-Gang Zhang; Dan Feng; Li-Xin Xie
Journal:  Curr Ther Res Clin Exp       Date:  2013-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.